Catalent, Inc.

Delisted

CIK 0001596783Large AcceleratedPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2024

Revenue

$4.38B

Net Income

$-1.04B

Total Assets

$9.75B

Equity

$3.60B

Shares Out

181.51M

Op. Cash Flow

$268.00M

Business

Catalent, Inc. provides development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. It offers formulation, analytical, clinical supply, fill-finish, and specialized delivery technologies including softgels, Zydis orally disintegrating tablets, gummies/soft chews, inhaled and nasal forms, GPEx cell-line platforms, AAV and viral vectors, pDNA, iPSC capabilities, and related packaging and cold-chain services. The company reports two principal segments: Biologics and Pharma and Consumer Health, covering advanced biologics, cell and gene therapies, and oral and topical dose forms. Catalent serves global pharmaceutical, biotechnology, and consumer health customers through approximately fifty facilities and an international distribution and clinical supply network.

Summary from filing dated 2024-09-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Net revenue	4,381	4,263	4,802	3,998	3,094
Cost of sales	3,428	3,223	3,188	2,646	2,111
Gross margin	953	1,040	1,614	1,352	983
Selling, general, and administrative expenses	935	829	844	687	577
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	0	0	−1	−182	1
Other Cost and Expense, Operating	80	164	41	19	11
Operating earnings	−749	−163	730	828	394
Interest expense, net	254	186	123	110	126
Other (Income)/expense, net	24	7	28	−3	−8
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	−1,027	−342	579	715	260
Income tax expense	16	−86	80	130	39
Net earnings attributable to Catalent	−1,043	−256	499	585	221
Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic	0	0	−16	−56	−48
Net Income (Loss) Available to Common Stockholders, Basic	−1,043	−256	483	529	173
Earnings Per Share, Basic	−5.76	−1.42	2.74	3.15	1.16
Earnings Per Share, Diluted	−5.76	−1.42	2.73	3.11	1.14
Goodwill, Impairment Loss	687	210	0	0	0

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Cash and cash equivalents	289	280	449	896	953
Trade receivables, net	921	1,002	1,051	1,012	838
Inventories	574	777	702	563	324
Prepaid Expense and Other Assets, Current	813	633	626	376	178
Total current assets	2,597	2,692	2,917	2,918	2,293
Property, plant, and equipment, net	3,643	3,682	3,127	2,524	1,901
Goodwill	2,333	3,039	3,006	2,519	2,471
Other intangibles, net	841	980	1,060	817	889
Deferred Income Tax Assets, Net	7	55	—	—	—
Other Assets, Noncurrent	332	329	349	268	174
Total assets	9,753	10,777	10,508	9,112	7,777
Debt, Current	48	536	31	75	73
Accounts payable	361	424	421	385	321
Other accrued liabilities	622	570	646	736	499
Total current liabilities	1,031	1,530	1,098	1,196	893
Long-term Debt and Finance Lease Obligations	4,857	4,313	4,171	3,166	2,945
Pension liability	95	100	103	137	135
Deferred Income Tax Liabilities, Net	5	76	—	—	—
Other liabilities	161	147	164	175	204
Total liabilities	6,149	6,166	5,733	4,838	4,271
Redeemable Preferred Stock Outstandings	0	0	0	359	607
Common Stock, Shares Authorized	1,000	1,000	1,000	1,000	1,000
Common Stock, Value, Outstanding	2	2	2	2	2
Preferred Stock, Value, Outstanding	0	0	0	0	0
Additional paid in capital	4,787	4,701	4,649	4,205	3,818
Accumulated deficit	−781	262	518	25	−535
Accumulated Other Comprehensive Income (Loss), Net of Tax	−404	−354	−394	−317	−386
Total shareholders equity	3,604	4,611	4,775	3,915	2,899
Total liabilities, redeemable preferred stock, and shareholders equity	9,753	10,777	10,508	9,112	7,777

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Proceeds from Sale and Maturity of Marketable Securities	0	89	—	—	—
Payments to Acquire Debt Securities, Available-for-sale	—	89	20	72	0
Proceeds from sale of property and equipment	1	8	0	0	0
Settlement on from sale of subsidiaries	0	0	−3	—	—
Proceeds from Divestiture of Interest in Consolidated Subsidiaries	—	0	−3	287	21
Payment for acquisitions, net of cash acquired	0	−474	−1,199	−147	−379
Payments to Acquire Investments	1	2	2	31	3
Segment, Expenditure, Addition to Long-Lived Assets	−327	−576	−660	−686	—
Net cash (used in) investing activities	−327	−955	−1,884	−649	−827
Proceeds from borrowing, net	1,200	715	1,100	166	909
Repayments of Long-term Debt	−1,116	−230	−78	−67	−860
Payments of Debt Issuance Costs	−16	−4	−15	−19	−25
Payments of Ordinary Dividends	0	0	4	22	—
Proceeds from Stock Options Exercised	9	4	26	38	0
Proceeds from (Payments for) Other Financing Activities	−3	36	12	10	0
Net cash provided by/(used in) financing activities	74	521	1,031	142	1,002
Depreciation and Amortization	489	422	378	289	254
Foreign Currency Transaction Gain (Loss), before Tax	13	−9	30	−4	2
Amortization and write-off of debt financing costs	14	8	7	11	12
Gain (Loss) on Sale of Assets and Asset Impairment Charges	−29	−98	−31	−9	−5
Derivative, Gain (Loss) on Derivative, Net	—	−2	−2	−17	−3
Equity compensation	68	35	54	51	48
Provision/(benefit) for deferred income taxes	−28	−127	9	64	2
Provision for bad debts and inventory	82	143	17	41	10
(Increase)/decrease in trade receivables	79	53	−73	−186	−151
(Increase)/decrease in inventories	109	−192	−128	−260	−76
Increase/(decrease) in accounts payable	−84	−21	37	50	72
Other assets/accrued liabilities, net - current and non-current	−166	−128	−423	−36	33
Net Cash Provided by (Used in) Operating Activities, Total	268	254	439	433	440
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	−6	11	−33	17	−7
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	9	−169	−447	−57	608
Stock Issued During Period, Value, Conversion of Convertible Securities	0	0	362	253	0
Interest paid	226	188	116	105	98
Income taxes paid, net	43	99	53	47	43
Capital Expenditures Incurred but Not yet Paid	24	18	6	—	—
Restructuring Reserve, Settled without Cash	7	18	0	—	—
Debtor Reorganization Items, Pension and Other Postretirement Related Charges	12	—	—	—	—
Other Operating Activities, Cash Flow Statement	1	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro